Standardization of lipid, lipoprotein, and apolipoprotein measurements
- PMID: 3042206
Standardization of lipid, lipoprotein, and apolipoprotein measurements
Abstract
Accurate laboratory measurement of serum cholesterol has become a national public health priority. National proficiency testing surveys indicate that laboratory inaccuracy in cholesterol testing is more of a problem than precision. Like precision, accuracy is a function of multiple pre-analytical and analytical sources of variation. Controlling pre-analytical sources of variation helps minimize such sources of variation as intraperson biological, behavioral, and clinical differences, and variations caused by sample collection, handling, and shipping. Standardization of analytical sources of variation helps to achieve and maintain desirable analytical performance, accurate reporting, and correct interpretation of a reported cholesterol result. The intraperson total variation in lipoproteins and their constituents is of primary interest when one is interpreting a single result or a series of results from a single person. The mean of multiple specimens from the same person is required if one is to obtain an accurate value for intraperson total cholesterol and minimize pre-analytical sources of variation. Standardizing analytical sources of variation in some instrument systems requires standardizing results by using "fresh" patients' specimens.
Similar articles
-
Reliability of lipid, lipoprotein, and apolipoprotein measurements.Clin Chem. 1988;34(8B):B84-94. Clin Chem. 1988. PMID: 3042204 Review.
-
Blood lipid measurements. Variations and practical utility.JAMA. 1992 Mar 25;267(12):1652-60. JAMA. 1992. PMID: 1542176 Review.
-
The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements.Clin Lab Med. 1989 Mar;9(1):105-35. Clin Lab Med. 1989. PMID: 2538292 Review.
-
Point: status of lipid and lipoprotein standardization.Clin Chem. 1997 Aug;43(8 Pt 1):1306-10. Clin Chem. 1997. PMID: 9267305
-
Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health.Am J Epidemiol. 1999 Dec 1;150(11):1229-37. doi: 10.1093/oxfordjournals.aje.a009950. Am J Epidemiol. 1999. PMID: 10588084
Cited by
-
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.Cardiovasc Drugs Ther. 2016 Oct;30(5):473-483. doi: 10.1007/s10557-016-6685-y. Cardiovasc Drugs Ther. 2016. PMID: 27618825 Free PMC article. Clinical Trial.
-
Effect of biological and analytical variation in cholesterol measurement on the cost-effectiveness of cholesterol-lowering therapy.Pharmacoeconomics. 1992 Nov;2(5):414-21. doi: 10.2165/00019053-199202050-00009. Pharmacoeconomics. 1992. PMID: 10147054
-
A genome-wide association study of childhood adiposity and blood lipids.Wellcome Open Res. 2023 Mar 23;6:303. doi: 10.12688/wellcomeopenres.16928.2. eCollection 2021. Wellcome Open Res. 2023. PMID: 39301199 Free PMC article.
-
Effects of pre-analytical processes on blood samples used in metabolomics studies.Anal Bioanal Chem. 2015 Jul;407(17):4879-92. doi: 10.1007/s00216-015-8565-x. Epub 2015 Mar 4. Anal Bioanal Chem. 2015. PMID: 25736245 Free PMC article.
-
Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.Hepatol Int. 2010 Aug 12;4(4):741-8. doi: 10.1007/s12072-010-9202-6. Hepatol Int. 2010. PMID: 21286345 Free PMC article.